Pulmicort pMDI HFA
ApprovedSmall molecule
AstraZenecaPulmicort pMDI HFA is one of 45 small molecule programs targeting Emphysema. It is currently in Approved.
2
Indications
7
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Pulmicort pMDI HFA
AstraZenecaApproved
Xolair
RochePreclinical
Cinqair
TevaPreclinical
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Qvar
Chiesi Farmaceutici S.p.A.Preclinical
Atrovent
Boehringer IngelheimPreclinical
Arcoxia
NovartisPreclinical
Symbicort
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Aciphex
Akero TherapeuticsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Asthma3 trials
Budesonide1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pulmicort pMDI HFA. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company